Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022 | Your money
PRINCETON, NJ, December 21, 2021 (GLOBE NEWSWIRE) – Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat the ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences:
LifeSci Partners 11th Annual Business Access Event – Wednesday January 5, 2022 JP Morgan Healthcare 40th Annual Conference – Wednesday January 12, 2022 5:15 PM EST
A live webcast of the 40th Annual JP Morgan Healthcare Conference will be available on the company’s website at www.oysterpointrx.com in the “Events and presentations” section. The link will be active for up to 30 days.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYATM nasal spray (varenicline solution) for the treatment of signs and symptoms of dry eye. Oyster Point has a growing portfolio of clinical and preclinical programs and continues to expand its research and development portfolio through internal innovation and external collaborations. Oyster Point continually strives to advance cutting-edge science and provide therapies to address the unmet needs of patients with ophthalmic disease and the eye care professionals who care for them. For more information visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.
Investor contact: Tim McCarthy LifeSci Advisors, LLC (212) 915-2564 [email protected]
Media Contact: Sheryl Seapy Real Chemistry (213) 262-9390 [email protected]
Copyright 2021 GlobeNewswire, Inc.